Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.

PMID:
21628408
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.

Shuqing L, Jianmin Y, Chongmei H, Hui C, Wang J.

Exp Hematol. 2011 Dec;39(12):1117-8. doi: 10.1016/j.exphem.2011.09.003. Epub 2011 Sep 12. No abstract available.

PMID:
21920470
[PubMed - indexed for MEDLINE]
3.

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L.

Haematologica. 2014 Feb;99(2):353-9. doi: 10.3324/haematol.2013.088211. Epub 2013 Nov 8.

PMID:
24213147
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK.

Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.

PMID:
21289309
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B.

Br J Haematol. 2008 Mar;140(6):625-34. doi: 10.1111/j.1365-2141.2007.06921.x.

PMID:
18302711
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
[PubMed - indexed for MEDLINE]
7.

Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

Chen MH, Qi C, Reece D, Chang H.

Hum Pathol. 2012 Jun;43(6):858-64. doi: 10.1016/j.humpath.2011.07.013. Epub 2011 Nov 1.

PMID:
22047644
[PubMed - indexed for MEDLINE]
8.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.

PMID:
20124509
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.

Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A.

Leuk Lymphoma. 2012 Jun;53(6):1174-82. doi: 10.3109/10428194.2011.637212. Epub 2011 Dec 6.

PMID:
22054286
[PubMed - indexed for MEDLINE]
10.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK.

Blood. 2011 Nov 3;118(18):4771-9. doi: 10.1182/blood-2011-05-356063. Epub 2011 Aug 22.

PMID:
21860026
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.

Blood. 2007 Apr 15;109(8):3177-88. Epub 2006 Dec 21.

PMID:
17185464
[PubMed - indexed for MEDLINE]
Free Article
12.

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2009 Nov;147(3):347-51. doi: 10.1111/j.1365-2141.2009.07864.x. Epub 2009 Aug 21.

PMID:
19702643
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.

Yuan J, Shah R, Kulharya A, Ustun C.

Leuk Res. 2010 Jul;34(7):954-7. doi: 10.1016/j.leukres.2010.01.013.

PMID:
20138360
[PubMed - indexed for MEDLINE]
14.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.

van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Barlogie B.

Blood. 2010 Aug 26;116(8):1220-7. doi: 10.1182/blood-2010-01-264333. Epub 2010 May 25.

PMID:
20501894
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.

Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.

PMID:
23536725
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group.

Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638.

PMID:
19252175
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ.

Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29.

PMID:
22932796
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.

Balsas P, Galán-Malo P, Marzo I, Naval J.

Leuk Res. 2012 Feb;36(2):212-8. doi: 10.1016/j.leukres.2011.09.011. Epub 2011 Oct 5.

PMID:
21978467
[PubMed - indexed for MEDLINE]
19.

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ.

Blood. 2011 Dec 8;118(24):6368-79. doi: 10.1182/blood-2011-06-363911. Epub 2011 Sep 13.

PMID:
21917757
[PubMed - indexed for MEDLINE]
Free Article
20.

CXCR4 is a good survival prognostic indicator in multiple myeloma patients.

Bao L, Lai Y, Liu Y, Qin Y, Zhao X, Lu X, Jiang Q, Lu J, Huang X.

Leuk Res. 2013 Sep;37(9):1083-8. doi: 10.1016/j.leukres.2013.06.002. Epub 2013 Jul 11.

PMID:
23849988
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk